•
AD
ADIL
Adial Pharmaceuticals, Inc
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
6.01M
Volume
198.89K
52W High
$1.30
52W Low
$0.21
Open
$0.21
Prev Close
$0.22
Day Range
0.21 - 0.22
About Adial Pharmaceuticals, Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
Latest News
Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045
GlobeNewswire Inc.•Jan 14
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
GlobeNewswire Inc.•Oct 17
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight
GlobeNewswire Inc.•Apr 28
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
GlobeNewswire Inc.•Feb 25
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
GlobeNewswire Inc.•Jan 29
Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight
GlobeNewswire Inc.•Dec 11
EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder - Benzinga
Benzinga•Jul 23
Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder
GlobeNewswire Inc.•Jun 20